MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial.

MLA

Gebrehiwet, Paulos, et al. “MiToS and King’s Staging as Clinical Outcome Measures in ALS: A Retrospective Analysis of the FORTITUDE-ALS Trial.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, vol. 24, no. 3/4, May 2023, pp. 304–10. EBSCOhost, https://doi.org/10.1080/21678421.2022.2154678.

APA

Gebrehiwet, P., Meng, L., Rudnicki, S. A., Sarocco, P., Wei, J., Wolff, A. A., Chiò, A., Andrews, J. A., Genge, A., Jackson, C. E., Lechtzin, N., Miller, T. M., & Shefner, J. M. (2023). MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 24(3/4), 304–310. https://doi.org/10.1080/21678421.2022.2154678

Chicago

Gebrehiwet, Paulos, Lisa Meng, Stacy A. Rudnicki, Phil Sarocco, Jenny Wei, Andrew A. Wolff, Adriano Chiò, et al. 2023. “MiToS and King’s Staging as Clinical Outcome Measures in ALS: A Retrospective Analysis of the FORTITUDE-ALS Trial.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 24 (3/4): 304–10. doi:10.1080/21678421.2022.2154678.